Leukemia Research Reports · 2014 · 79 citations · 8 references
MedicineHematologyPharmacologyChemotherapyClinical PharmacologyHematologic OncologyHematologic Malignancy PharmacotherapyHematologic Malignancy TherapyHematologic ToxicityMyelodysplastic SyndromesTyrosine Kinase InhibitorsAcute Myeloid Leukemia TherapyAcute Myeloid Leukemia TreatmentAurora Kinase InhibitionAurora Kinase SignalingCancer Cell SenescenceCell SenescenceMyelodysplastic Syndrome TherapyMyelodysplastic Syndrome Treatment
Alisertib (MLN8237) is an investigational, oral, selective, Aurora A kinase (AAK) inhibitor. In this phase 2 trial, 57 patients with acute myeloid leukemia (AML) or high-grade myelodysplastic syndrome received alisertib 50 mg BID for 7 days in 21-day cycles. Responses in 6/35 AML patients (17% response rate with an additional 49% stable disease, 34% transfusion independence) included 1 complete response lasting >1 year. No responses were observed in MDS patients. Adverse events >30% included diarrhea, fatigue, nausea, febrile neutropenia, and stomatitis. Results suggest modest activity in AML, supporting further research to better understand how AAK inhibition may induce leukemic cell senescence.
8
Bruce D. Cheson, John M. Bennett, Thomas Büchner et al. · Journal of Clinical Oncology · 2003 · 2.7K citations
Medicine, Hematology, Oncology +17
Elizabeth Claire Dees, Roger B. Cohen, Margaret von Mehren et al. · Clinical Cancer Research · 2012 · 156 citations · Full text